FH and monoclonal gammopathy: We believe this approach would provide a more accurate estimation of the contribution of acquired risk factors (anti-FH autoantibodies) in identifying the etiological factors underlying complement-mediated diseases such as aHUS and C3G and would be particularly valuable in the context of monoclonal gammopathy.